Shingrix Vaccine: What It Is, How It Works, and Who Should Get It

What Is Shingrix and Why It Matters

Shingrix is a recombinant, adjuvanted shingles (herpes zoster) vaccine designed to help older adults and eligible immunocompromised people prevent shingles and its complications, including postherpetic neuralgia. Unlike the earlier live Zoster vaccine (ZVL), Shingrix is not made with live virus and instead uses a virus-like particle to provoke a strong immune response. Because shingles risk rises with age and can lead to persistent nerve pain, major health authorities generally recommend Shingrix for most adults 50 years and older and for immunocompromised adults 19 years and older, regardless of prior shingles or previous ZVL vaccination.

How Shingrix Works in the Body

Shingrix is a subunit, recombinant vaccine that contains a glycoprotein E (gE) antigen from varicella-zoster virus combined with a proprietary adjuvant called AS01B. The adjuvant boosts and directs the immune response, helping the body produce antibodies and T cells that target the virus if it reactivates. Because the product does not contain whole virus or live components, it cannot cause shingles. The robust immune training it creates is the main reason Shingrix has shown higher effectiveness across age groups than the earlier ZVL vaccine.

Immune Memory After Shingrix

After vaccination, the immune system learns to recognize the varicella-zoster virus gE protein, which is consistently present on the surface of the dormant virus in nerve cells. If the virus later reactivates, memory B cells and T cells can respond more quickly, often preventing rash development or reducing severity and duration. This cellular and humoral response underpins the vaccine’s long-term effectiveness in preventing shingles and related neuralgia, even as immunity may wane over many years.

Who Should Get Shingrix

• Adults aged 50 years and older, regardless of prior shingles or prior ZVL (Zostavax) vaccination.
• Adults aged 19 years and older who are or will be immunocompromised due to disease or therapy (e.g., hematologic malignancies, solid organ or stem cell transplant, HIV with low CD4, immunosuppressive drugs).
• Adults who have already had shingles: vaccination is recommended after recovery to prevent future episodes.
• Adults with no documented prior varicella infection should still discuss vaccination with a clinician; if seronegative, the varicella vaccine may be considered first.

Dosing Schedule and Timing

Shingrix is delivered as two intramuscular doses, typically in the upper arm. The second dose is generally given 2 to 6 months after the first; schedules approved for specific ages and immunocompromised use may vary slightly based on national guidance. People who have recently had shingles should usually wait until the acute phase has resolved and the rash has healed before starting the series. There is no need to restart the series if a longer interval elapses between doses, though earlier completion is ideal. Shingrix can be administered with other vaccines, including influenza and Tdap, at the same visit when feasible.

Timing Around Other Vaccines

If you recently received another vaccine, you can usually proceed with Shingrix, but your clinician may recommend spacing based on your clinical situation. For people who are or may become pregnant, pregnancy should be avoided during the Shingrix series and for about one month after the final dose, as the vaccine is not recommended during pregnancy. Those who are breastfeeding may generally receive Shingrix; consult your healthcare provider for personalized advice.

Common Side Effects and Management

Systemic and local reactions are common after Shingrix and are signs of immune activation. Most are mild to moderate, resolve within 2 to 3 days, and can be managed with rest, fluids, and over-the-counter pain relief as advised by a clinician. Side effects are more frequent after the second dose and may be more intense in older age groups. If reactions appear severe or persistent, or if you experience worrisome symptoms such as difficulty breathing, seek medical attention promptly. Reported side effects include:

• Local injection-site pain, erythema, and swelling
• Systemic reactions such as fatigue, headache, shivering, fever, and upset stomach
• Symptoms often peak within 24 to 48 hours after dosing
• Symptoms do not typically indicate an allergic reaction but should be discussed with a clinician if severe

Effectiveness and Real-World Impact

Clinical trials and post-licensure data consistently show Shingrix to be highly effective at preventing shingles and postherpetic neuralgia across a wide age range. Effectiveness remains high in older adults, where shingles risk and severity are greatest. Waning protection, new variants of virus reactivation, and underuse in eligible populations are active areas of ongoing study. Public health data support that widespread Shingrix use can significantly reduce shingles incidence, healthcare visits, and the burden of chronic nerve pain. These data inform continued recommendations and guidance for catch-up and special populations.

Reported Vaccine Effectiveness (Approximate)

Contraindications, Precautions, and Special Considerations

Shingrix should not be started by people who had a severe allergic reaction (e.g., anaphylaxis) to a prior dose or to any component of the vaccine. Minor illnesses, such as a cold, are generally not a reason to delay vaccination. Moderate or severe acute illness with or without fever should usually be postponed until recovery. Because of the importance of completing both doses for sustained protection, clinicians should make catch-up plans for those who delayed the second dose. There are no pregnancy-specific data, so use is generally avoided unless clearly needed; decisions should be individualized with a healthcare provider.

Practical Points for Vaccine Administration

• Shingrix is delivered as an intramuscular injection, typically in the deltoid muscle.
• Use a new, sterile syringe and needle for each dose to maintain safety and efficacy.
• Counsel recipients on common, usually self-limited reactions and when to seek medical care.
• Document lot number, expiration date, and site of administration in the medical record.
• Report significant adverse events to the appropriate vaccine adverse event reporting system per local regulations.

When to Seek Medical Advice

Contact a healthcare provider if you experienced a severe reaction after a prior dose, have a moderate or severe acute illness, are immunocompromised, are pregnant or planning pregnancy, or have questions about timing with other vaccines. Clinical guidance can help tailor the vaccine to your health profile and ensure safe, effective protection against shingles.

Bottom Line

Shingrix is a highly effective, non-live recombinant shingles vaccine recommended for most adults 50 years and older and for immunocompromised adults 19 years and older. It requires two doses given 2 to 6 months apart and is associated with common, generally mild side effects. For most people, Shingrix offers strong, long-lasting protection against shingles and its most troubling complication, postherpetic neuralgia.

Frequently Asked Questions

• Can I get Shingrix if I already had Zostavax? Yes; you should still receive Shingrix regardless of prior Zostavax vaccination, with at least eight weeks between Zostavax and the first Shingrix dose recommended by some guidelines.
• Do I need to restart the series if the second dose is delayed? No; you do not need to restart the series, but you should complete the second dose as soon as practicable to ensure full protection.
• Is Shingrix safe if I have a history of allergies? Discuss any history of severe allergies with your clinician; the vaccine is contraindicated only after a severe allergic reaction to a prior dose or a component of Shingrix.
• Does Shingrix contain any live virus? No; Shingrix is a recombinant, non-live vaccine and cannot cause shingles.
• How long does protection from Shingrix last? Data indicate durable protection for at least several years; research is ongoing to characterize long-term duration and potential booster needs.